By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Alder Biopharmaceuticals Inc. 

Corporate Headquarters
11804 North Creek Parkway South
Bothell  Washington  98011  U.S.A.
Phone: 425-205-2900 Fax: 425-205-2901


Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, ALD403, is being evaluated for migraine prevention. ALD403 is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

At Alder we seek talented contributors who thrive in a high-energy team environment and want to make a real and lasting impact in the field of antibody therapeutics. Alder teams are creative, collaborative, open, committed--and central to the success of this company and its mission. If this is the kind of company you want to work for, we want to hear from you.

Key Statistics

Ownership: Private

Web Site: Alder Biopharma


Company News
Alder Biopharma Presents Additional Data From Eptinezumab Development Program At 69th Annual American Academy of Neurology Meeting 4/24/2017 8:23:39 AM
Alder Biopharma To Host Conference Call To Discuss First Quarter 2017 Financial And Operating Results 4/20/2017 8:07:06 AM
10 Biotech Stocks that Could Blow Up in Q3 7/6/2016 6:56:11 AM
Amgen (AMGN) Shows Off Mid-Stage Migraine Data, Needs to Compete With Eli Lilly (LLY), Teva (TEVA) and Alder Biopharma 6/9/2016 5:54:09 AM
Alder Biopharma Appoints Roger Cady, M.D., Vice President Of Neurology 6/6/2016 3:59:30 PM
Alder Biopharma To Hold Conference Call On Monday, March 28, At 8:30 Am ET 3/28/2016 8:01:20 AM
Alder Biopharma's Migraine Drug Meets Primary and Secondary Endpoints in Phase 2b Trial 3/28/2016 6:34:33 AM
Five Companies Face Big FDA Decisions This Month 3/14/2016 6:39:10 AM
Alder Biopharma Reports Fourth Quarter And Full Year 2015 Financial And Operating Results 2/24/2016 10:51:20 AM
Alder Biopharma Strengthens And Expands Leadership Team Supporting Advancement Of ALD403 Toward Future Commercialization 2/9/2016 8:02:21 AM